Morgan Stanley Sees Growth Platforms Building for Stericycle
In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Stericycle (NASDAQ: SRCL).
In the report, Morgan Stanley noted, “Organic revenue growth in 4Q13 ticked up slightly versus 3Q13 but remains consistent with 2012-13 trends. Greater traction from StrongPak is a modest positive but drove margin dilution. Full valuation and limited visibility on sustainable growth acceleration keeps us from a more constructive view.”
Stericycle closed on Wednesday at $116.48.
Latest Ratings for SRCL
|Nov 2014||Bank of America||Maintains||Buy|
|Sep 2014||Goldman Sachs||Downgrades||Buy||Neutral|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.